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patients were diabetic at baseline, there is no information regard-
ing the glucose tolerance status of the other subjects. It is well
known that NAFLD is strongly associated with obesity, hyperten-
sion, dyslipidemia and also glucose tolerance abnormalities [5].
In addition, all these metabolic problems are risk factors for
DM and also prediabetes. In light of these data, we think that
some of the study participants may still have overt glucose dys-
regulation or DM without implementation of the glucose toler-
ance test. Secondly, there is no data about the blood pressure
and lipid proﬁles of the study participants. A large body of evi-
dence shows that circulating levels of hsCRP differ according to
the degree of lipid disorders [6]. This point is also true for hyper-
tension or elevated blood pressure [7]. On the other hand, meta-
bolic syndrome is also strongly associated with circulating hsCRP
levels [8]. Lastly, no information about the medications could be
seen in the text. We know that hsCRP levels are easily affected
from the medications started for the metabolic problems men-
tioned above [9,10]. Collectively, all these points raise several
questions warranting discussion.
We conclude that, before making certain interpretations, pres-
ence of major confounders raises some questions about the data
presented. In such a case, statistical correlations may also be mis-
leading. It would be appreciated if the authors could present
some more data adjusted for topics mentioned above. This could
provide the readers of the Journal clearer information regarding
the relationship of hsCRP with this clinically relevant condition.
Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
References
[1] Yoneda M et al. High-sensitivity C-reactive protein is an independent clinical
feature of nonalcoholic steatohepatitis (NASH) and also of the severity of
ﬁbrosis in NASH. J Gastroenterol 2007;42 (7):573–582.
[2] Zimmermann E et al. C-reactive protein levels in relation to various
features of non-alcoholic fatty liver disease among obese patients. J Hepatol
2011;55:660–665.
[3] Garcia C et al. Diabetes and inﬂammation: fundamental aspects and clinical
implications. Diabetes Metab 2010;36 (5):327–338.
[4] Sabanayagam C et al. Serum C-reactive protein level and prediabetes in two
Asian populations. Diabetologia 2011;54 (4):767–775.
[5] Yun JW et al. Abnormal glucose tolerance in young male patients with
nonalcoholic fatty liver disease. Liver Int 2009;29:525–529.
[6] Nordestgaard BG, Zacho J. Lipids, atherosclerosis and CVD risk: is CRP an
innocent bystander? Nutr Metab Cardiovasc Dis 2009;19 (8):521–524.
[7] Schillaci G, Pirro M. C-reactive protein in hypertension: clinical signiﬁcance
and predictive value. Nutr Metab Cardiovasc Dis 2006;16 (7):500–508.
[8] Ndumele CE, Steatosis Hepatic, et al. Obesity, and the metabolic syndrome
are independently and additively associated with increased systemic
inﬂammation. Arterioscler Thromb Vasc Biol 2011, [Epub ahead of print].
[9] Dandona P. Effects of antidiabetic and antihyperlipidemic agents on
C-reactive protein. Mayo Clin Proc 2008;83 (3):333–342.
[10] Dandona P et al. Angiotensin II and inﬂammation: the effect of angiotensin-
converting enzyme inhibition and angiotensin II receptor blockade. J Hum
Hypertens 2007;21 (1):20–27.
Teoman Dogru
Halil Genc
Sait Bagci
Department of Gastroenterology,
Gulhane School of Medicine, Etlik,
Ankara, Turkey
E-mail address: teomandogru@yahoo.com (J. Dogru)
Reply to: ‘‘C-reactive protein levels in non-alcoholic fatty
liver disease’’
Letters to the EditorTo the Editor:
We thank Dr. Dogru et al. for their comments on our paper on
C-reactive protein (CRP) levels in relation to various features of
non-alcoholic fatty liver disease (NAFLD) among obese patients
[1]. In our study of 627 obese adults with liver histology and
measures of body mass index (BMI, kg/m2), and high sensitivity
(hs)-CRP, we conﬁrmed a strong association between BMI and
hs-CRP, with a 20% increase in hs-CRP level per 10% increase in
BMI. Also, we observed a positive association between hs-CRP
and liver steatosis, but no BMI independent association between
hs-CRP and non-alcoholic steato-hepatitis (NASH), hence ques-
tioning whether CRP can be used as a marker of severity of NAFLD
[1].
We fully acknowledge that circulating hs-CRP levels may not
only associate with obesity, but also with pre-diabetes and dia-
betes [2,3], which in turn may associate with NAFLD [4]. How-
ever, obesity (which was adjusted for by use of BMI) is also
strongly associated with both diabetes and NAFLD [5]. Therefore,
further adjustment for diabetes or glucose tolerance abnormali-
ties would not be expected to change our results notably. The
same argument holds for the effect of further adjustment for
hypertension and lipid proﬁles. Still, to meet the concern of508 Journal of Hepatology 2Dr. Dogru et al., we have reassessed the mentioned metabolic
factors in two of the study cohorts. We can now report that in
the OBBO cohort, hs-CRP was associated with triglycerides
(p = 0.02), but not with glucose tolerance status (test across cat-
egories of normal glucose tolerance, impaired fasting glucose
[IFG], impaired glucose tolerance [IGT], combined IFG-IGT, and
diabetes), systolic or diastolic blood pressure, total cholesterol,
HDL-cholesterol, or LDL-cholesterol. In the Nice Obese Subjects
cohort, we observed a negative association between CRP and
high blood pressure (p = 0.002), but no association between
CRP and, respectively, diabetes, glucose intolerance, triglyceride
levels, HDL-cholesterol, or the metabolic syndrome. Hence,
adjustment for triglycerides and blood pressure could be consid-
ered, but would, due to the association with BMI, not be
expected to change conclusions.
An additional concern raised by Dr. Dogru et al. was the effect
of medications on the observed associations. A reduction in hs-
CRP caused by medications given primarily to patients with
severe metabolic disturbances and related severe NAFLD, could
hypothetically explain our ﬁnding of no association between
hs-CRP levels and severity of NAFLD. Our reassessment of the
OBBO cohort revealed that hs-CRP was not associated with012 vol. 56 j 503–510
medications for diabetes (used by 2%) or medications for blood
pressure (used by 35%), whereas a negative association between
hs-CRP and medication for lipid disturbances, which was used by
14%, was observed (p = 0.04). It must be carefully considered, if
additional adjustment for medications for lipid disturbances
would be justiﬁable in light of the aim of the study, and how they
would affect the interpretation of our results. Our primary aim
was to test whether hs-CRP could be used as a BMI independent
biomarker for severity of NAFLD as an alternative to an invasive
procedure, namely the liver biopsy. Adjustment for the medica-
tions for lipid disturbances (had they been available for all three
sub-cohorts) would potentially have changed the observed asso-
ciation between hs-CRP and NAFLD, but it would not be expected
to change the fact, that this association between hs-CRP and
NAFLD is not BMI independent.
To summarize, we believe that additional adjustments would
not add to the interpretation of our results and may potentially
cause over-adjustment. As a parallel example, the inﬂuence of
adjusting or not adjusting for weight, when assessing the associ-
ation between birth weight and blood pressure, has been exam-
ined [6]. This mathematical example illustrated how a genuine
inverse relation between birth weight and blood pressure would
be exaggerated by adjusting for current weight, whereas a posi-
tive relation between birth weight and blood pressure was
reversed by adjusting for current weight [6]. In consequence, by
adjusting further for the suggested metabolic factors in the pres-
ent study, we might end up with an over-adjustment leading to
an even stronger rejection of the hypothesis of CRP being a mar-
ker of NAFLD.
In conclusion, we thank Dr. Dogru et al. for bringing these
important issues up for discussion, and we adhere to the conclu-
sion, that hs-CRP is a marker of liver steatosis, but not a BMI inde-
pendent marker of level of NAFLD.
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